A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-<i>κ</i>B Signal Pathway and Reducing Reactive Oxygen Species

<div>Establishment of the RANKL crystal model. (a) A potential binding site for DIC in a hydrophobic domain containing hydrogen-bond accepter and donor was predicted. (b, c) The binding site for Rob docking began at residues GLN236 and extended toward ASN294. (d, e) A strong affinity between DIC and RANKL was observed in computational docking.</div>

Oxidative Medicine and Cellular Longevity

fig1

Figure 1

Figure 1: A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-<i>κ</i>B Signal Pathway and Reducing Reactive Oxygen Species 

Figure 1 | A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-κB Signal Pathway and Reducing Reactive Oxygen Species 